

ATLANTIC GENERAL HOSPITAL ONE OF SIX TREATMENT SITES FOR MONOCLONAL ANTIBODY THERAPY

Atlantic General Hospital is one of the first six treatment sites within the State of Maryland to offer the monoclonal antibody (MAb) therapeutic bamlanivimab and the cocktail of Casirivimab and Imdevimab for high-risk patients with mild to moderate COVID-19 infection.

As a provider in our community, here are the steps to determine if the patient is eligible for the MAbs therapy and how to schedule a patient's therapy. Please reference the **Maryland Referral Form for Ambulatory Monoclonal Infusion Treatment for COVID19** that was sent out by the Maryland Board of Medicine and is attached.

Registration Process for MAbs patients

1. Prescriber will complete the Maryland Referral Form for Ambulatory Antibody Infusion Treatment for COVID-19 form scanned into the patient's visit in the patient window.
2. E-mail forms to pharmacy@atlanticgeneral.org and fax the forms to 410-641-9708
3. Call the Scheduling Line at 410-641-9714 or 410-641-9605 to schedule the patient
4. Patient will be instructed on when and where to arrive for their infusion.

Patient Qualifications

The MAbs an infusion therapy granted emergency use authorization by the U.S. Food and Drug Administration for treatment of individuals with COVID-19 before severe symptoms occur, to reduce the chances of the infection worsening and requiring hospitalization.

Due to the limited doses available nationwide, treatment is only offered for adults and children ages 12 years and older at greatest risk of progressing to severe COVID-19, based upon specific criteria established by the FDA.

These criteria include being over the age of 65 years, having an underlying chronic condition like diabetes or severe obesity, and/or having a compromised immune system. The comprehensive FDA criteria can be found [here](#).

The MAbs should be administered as soon as possible after a positive COVID-19 test, as it is most beneficial when given early in symptom progression. It is administered via a single intravenous infusion and mimics immune system antibodies that block viruses.

Not all individuals who test positive for COVID-19 are recommended to receive MAbs. MAbs infusion is provided through physician referral only, after it is determined that a patient is a good candidate and at high risk of severe onset.

Please note that MAbs are not authorized for use inpatients:

- who are hospitalized due to COVID-19, or
- who require oxygen therapy due to COVID-19, or
- who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity

High-risk summary definitions are as follows, however, all healthcare providers should reference the authorized FDA materials related to MAbs prior to administering.

All Patients (who meet at least one of the following criteria):

- BMI \geq 35
- Chronic Kidney Disease
- Diabetes
- Immunosuppressive disease
- Receiving immunosuppressive treatment
- Age \geq 65 years
- Age \geq 55 years AND have any of the following:
 - Cardiovascular disease
 - Hypertension
 - COPD/other chronic respiratory disease

Adolescents (age 12-17 years) who meet at least one of the following criteria:

- BMI \geq 85th percentile for age/gender
- Sickle cell disease
- Congenital or acquired heart disease
- Neurodevelopmental disorders (e.g. cerebral palsy)
- Medical-related technological gastronomy, or positive pressure ventilation (not related to COVID-19)
- Asthma, reactive airway, or other chronic respiratory disease that requires daily medication for control

Individuals with COVID-19 symptoms should contact their primary care provider or visit the [Atlantic ImmediCare clinic in Ocean City](#) for testing and referral.